Article Information
History
- October 20, 2023.
Article Versions
- Version 1 (September 24, 2023 - 05:31).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Bijak Rabbani1,*,
- Sabrina Gabriel Tanu1,*,#,
- Kevin Nathanael Ramanto1,
- Jessica Audrienna1,
- Fatma Aldila1,
- Eric Aria Fernandez1,
- Mar Gonzalez-Porta1,
- Margareta Deidre Valeska1,
- Jessline Haruman1,
- Lorina Handayani Ulag1,
- Yusuf Maulana1,
- Kathleen Irena Junusmin1,
- Margareta Amelia1,
- Gabriella Gabriella1,
- Feilicia Soetyono1,
- Aulian Fajarrahman1,
- Salma Syahfani Maudina Hasan1,
- Faustina Audrey Agatha2,
- Marco Wijaya2,
- Stevany Tiurma Br Sormin2,
- Levana Sani1,
- Soegianto Ali3,
- Astrid Irwanto1 and
- Samuel J Haryono2
- 1Nalagenetics Pte Ltd, 1093 Lower Delta Road, #04-05/06/07/08, Singapore 169204
- 2SJH Initiatives, MRCCC Siloam Hospitals Semanggi, Jakarta Indonesia
- 3Biomedicine department, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia
- ↵#Corresponding author; email: clinicalstudies{at}nalagenetics.com
Posted October 20, 2023.
A combined risk model shows viability for personalized breast cancer risk assessment in the Indonesian population
